Celtic Biotech

Celtic Biotech is developing novel, clinical trial-phase products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients.

Latest News

June 2, 2015 Spotlight Innovation subsidiary Celtic Biotech retains the FreeMind Group to identify, prepare, and file for research and development grant opportunities Read more...
May 20, 2015 ImmunoClin Ltd. to provide Contract Research Organization (CRO) services for Crotoxin Phase I Part II clinical trials for Spotlight Innovation subsidiary Celtic Biotech Read more...
April 06, 2015 Spotlight Innovation subsidiary Celtic Biotech product EPISORB available to compounding pharmacy industry Read more...
March 10, 2015 Spotlight Innovation subsidiary Celtic Biotech Iowa licenses promising therapy for Chronic Kidney Disease Read more...
January 15, 2015 Spotlight Innovation subsidiary Celtic Biotech Iowa granted Patent by the U.S. Patent and Trademark Office Read more...
December 4, 2014 Celtic Biotech Iowa requests reactivation and transfer of National Drug Code registration Read more...
June 10, 2014 Spotlight Innovation subsidiary Celtic Biotech Iowa, Inc., completes merger with Celtic Biotech Ltd. Read more...